Resource Use and Real-World Outcomes for Ranibizumab Treat and Extend for Neovascular Age-Related Macular Degeneration in the UK: Interim Results from TERRA

INTRODUCTION: Ranibizumab is an inhibitor of vascular endothelial growth factor-A (anti-VEGF) approved for the treatment of neovascular age-related macular degeneration (nAMD). The treat and extend (T&E) regimen can potentially reduce the burden of clinic visits compared with a pro re nata (PRN)...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yit, Downey, Louise, Mehta, Hemal, Mushtaq, Bushra, Narendran, Niro, Patel, Nishal, Patel, Praveen J., Ayan, Filis, Gibson, Kara, Igwe, Franklin, Jeffery, Pete
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5449310/
https://www.ncbi.nlm.nih.gov/pubmed/28508241
http://dx.doi.org/10.1007/s40123-017-0091-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5449310/
https://www.ncbi.nlm.nih.gov/pubmed/28508241
http://dx.doi.org/10.1007/s40123-017-0091-9

Ejemplares similares